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Abstract: Ischemic stroke is caused by a disruption in blood supply to a region of the brain. It induces
dysfunction of brain cells and networks, resulting in sudden neurological deficits. The cause of
stroke is vascular, but the consequences are neurological. Decades of research have focused on
finding new strategies to reduce the neural damage after cerebral ischemia. However, despite the
incredibly huge investment, all strategies targeting neuroprotection have failed to demonstrate
clinical efficacy. Today, treatment for stroke consists of dealing with the cause, attempting to remove
the occluding blood clot and recanalize the vessel. However, clinical evidence suggests that the
beneficial effect of post-stroke recanalization may be hampered by the occurrence of microvascular
reperfusion failure. In short: recanalization is not synonymous with reperfusion. Today, clinicians
are confronted with several challenges in acute stroke therapy, even after successful recanalization:
(1) induce reperfusion, (2) avoid hemorrhagic transformation (HT), and (3) avoid early or late vascular
reocclusion. All these parameters impact the restoration of cerebral blood flow after stroke. Recent
advances in understanding the molecular consequences of recanalization and reperfusion may lead
to innovative therapeutic strategies for improving reperfusion after stroke. In this review, we will
highlight the importance of restoring normal cerebral blood flow after stroke and outline molecular
mechanisms involved in blood flow regulation.
Keywords: stroke; reperfusion; collaterals; hemorrhagic transformation; no-reflow and reocclusion
1. Introduction
According to the World Health Organization (WHO), each year, 15 million people suffer a stroke
worldwide, of whom five million die and another five million show chronic disability [1,2]. Based on
clinical evidence of better outcomes and reduced mortality, early revascularization is a critical process
to rescuing salvageable tissue [3–6]. For the last 22 years, recanalization therapy has been induced
by intravenous (i.v.) administration of recombinant tissue plasminogen activator (rt-PA) [3,7]; but
recently, mechanical endovascular clot retrieval has also been approved, having shown effectiveness in
several clinical trials [4,8]. Endovascular thrombectomy has revolutionized the management of stroke.
It is one of the most effective treatments in medicine [4]. Indeed, although thrombolysis with rt-PA
was the only effective treatment for ischemic stroke for a long time, recanalization rates of i.v. rt-PA
have remained low in large artery occlusions [5,9–12]. For instance, in proximal middle cerebral artery
(MCA), internal carotid artery (ICA) or basilar artery occlusions, recanalization with i.v. rt-PA was
achieved in less than 20% of cases [11,13,14]. Today, by using thrombectomy approaches in large-vessel
occlusion, substantial reperfusion is achieved in 70–80% of cases.
The recanalization rates of first-generation thrombectomy devices was quite similar to those
with rt-PA. For instance, the first study of the thrombectomy devices Mechanical Embolus Removal
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in Cerebral Ischemia (MERCI), which was published in 2004, showed recanalization in only 43%
of patients [15]; and the follow up MULTI MERCI trial showed a recanalization rate of 55% [16,17].
The Penumbra aspiration system was then developed as a second-generation device, and the results
of the Penumbra Pivotal Stroke Trial were reported in 2008 [8]. This trial reported higher efficacy
in opening occluded blood vessels compared to those reported for the MERCI device, and with
equivalent safety (recanalization rates of 82%) [18]. In 2012, third-generation devices (SOLITAIRE and
Trevo) showed very promising recanalization rates (92–94%) and clinical outcomes, as reported in the
SOLITAIRE With the Intention For Thrombectomy trial (SWIFT), and Thrombectomy REvascularisation
of large-Vessel Occlusions (TREVO 2) trial [19,20]. Today, with advanced thrombectomy technology,
recanalization rates have dramatically improved, which is reflected in a better overall outcome for
treated patients compared to early studies.
Despite this success, 30% to 68% of stroke patients still have an unfavorable clinical outcome,
even after recanalization [21]. Similarly, after successful rt-PA thrombolysis, more than 50% of stroke
patients do not show any sign of clinical improvement [5]. This “futile recanalization” that occurs
after removal of the causative clot could be related to the occurrence of several vascular obstacles
that stem from the vascular compartment of the brain, and which may hamper recovery of cerebral
perfusion. For instance, clinical evidence suggests that some stroke patients do not show reperfusion
even when recanalization is successful [22,23]. This has been termed “futile recanalization”, and has
been attributed to the occurrence of the “no-reflow phenomenon” and/or arterial reocclusion [24,25].
The no-reflow phenomenon relates to the inability to reperfuse regions of the brain after ischemia,
despite removal of the artery occlusion. The mechanism involves microvascular obstruction [26].
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Figure 1. Vascular challenges for reperfusion therapy. (a) Schematic diagram of a coronal section of 
the brain. The middle cerebral artery (MCA) is occluded with a blood clot. The blue areas correspond 
to the infarct that could be saved with reperfusion therapy (b). The different possible pitfalls of 
reperfusion are shown as no recanalization (c), recanalization but no reperfusion and arterial 
reocclusion and no-reflow (d), and vascular complications: hemorrhagic transformation (e). In c–e, a 
summary of potential molecules involved in blood flow regulation is given for each scenario. 
Abbreviations: GPIIb/IIIa, glycoprotein IIb/IIIa receptors; VEGF, Vascular Endothelial Growth Factor; 
TAFI, Thrombin Activatable Fibrinolysis Inhibitor; PAI-1, Plasminogen Activator Inhibitor-1; ICAM-
1, Intercellular Adhesion Molecule 1; MMP, Matrix Metalloproteinases; PARP, Poly-ADP-Ribose 
Polymerase. 
Figure 1. Vascular challenges for rep rfusion therapy. (a) Schematic diagram of a cor nal section of the
brain. The middle cerebral artery (MCA) is occluded with a blood cl t. The blu areas correspond to the
infarct that could be save with reperfusion therapy (b). The different possible pitfalls of reperfusion
are shown as no recanalization (c), recanalization but no reperfusion and arterial reocclusion and
no-reflow (d), and vascular complications: he orrhagic transformation (e). In c–e, a summary of
potential molecules involved in blood flow regulation is given for each scenario. Abbreviations:
GPIIb/IIIa, glycoprotein IIb/IIIa receptors; VEGF, Vascular Endothelial Growth Factor; TAFI, Thrombin
Activatable Fibrinolysis Inhibitor; PAI-1, Plasminogen Activator Inhibitor-1; ICAM-1, Intercellular
Adhesion Molecule 1; MMP, Matrix Metalloproteinases; PARP, Poly-ADP-Ribose Polymerase.
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In summary, clinicians are confronted with several obstacles when attempting recanalization
therapy for stroke patients: (1) recanalization fails, (2) absence of reperfusion “no-reflow”
or “reocclusion”, and (3) vascular complications such as hemorrhagic transformation (HT).
These problems have been understudied, but with increasing use of thrombectomy in stroke, the
need to understand the vascular and cerebral blood flow (CBF) changes associated with recanalization
cannot be overemphasized. Each of these problems in reinstalling normal perfusion after stroke can
also be approached from the molecular level, since several genes and proteins are induced after stroke
and/or recanalization (Figure 1).
2. Recanalization Failure
2.1. Recanalization Rate
The first critical step in obtaining a favorable effect of reperfusion is to successfully re-open the
occluded vessel and allow restoration of antegrade perfusion to the ischemic territory. Clinical data
show that reperfusion therapies can result in different patterns of recanalization that can be complete,
partial or absent (Table 1). To evaluate the degree of reperfusion, some mechanical thrombectomy
studies have used the Thrombolysis In Cerebral Infarction (TICI) scoring system, which subdivides
partial reperfusions into two different categories: 2a and 2b. The 2a partial grade means that less
than two-thirds of the entire vascular territory is reperfused, while 2b recanalizations are almost
complete, but slower than normal (Table 1). However, in some other clinical trials, recanalization
has been evaluated according to the Thrombolysis in Myocardial Ischemia (TIMI) grading scale or
the Thrombolysis in Brain Ischemia (TIBI), but using these scores does not provide any details about
different partial patterns of recanalization.
After rt-PA thrombolysis, only 22% to 30% of patients have a complete recanalization; 23% to 48%
have partial recanalization; and in 22% to 41% of patients, recanalization completely fails [14,27–29].
The use of mechanical thrombectomy in different clinical studies is associated with higher reperfusion
success and less recanalization failure than rt-PA. For example, recanalization success reached more
than 90% in the Extending the time for Thrombolysis in Emergency Neurological Deficits–Intra-Arterial
(EXTEND-IA) randomized trial, and the rate of no recanalization was only 3% [30].
Table 1. Recanalization patterns after rt-PA thrombolysis in clinical studies.
Therapy
Recanalization
Successful Failed
References Complete Partial (2b) Partial No Recanalization
Thrombolysis
Christou et al., [27] 30% 40% 30%
Alexandrov et al., [28] 30% 48% 22%
Rubiera et al., [14] 22% 37% 41%
Saqqur et al., [29] 27% 23% 37%
Endovascular
Thrombectomy
MERCI [31] 24% 42% 33%
Penumbra [18] 18% 54% 28%
TREVO [20] 14% 78% 8%
MR CLEAN [32] 24% 35% 27% 14%
EXTEND-IA [30] 48% 38% 10% 3%
However, endovascular clot-retrieval therapy is only suitable for large arterial occlusions (internal
carotid artery (ICA) and proximal M1 middle cerebral artery (MCA)), representing nearly 50% of stroke
cases [33,34]. Smaller arteries present a real technical challenge for thrombectomy and recanalization,
with intravenous thrombolysis remaining the most suitable strategy for these occlusions.
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In addition to the approach used, recanalization success varies among stroke patients depending
on the location and composition of the occluding clot as well as the collateral flow. Evidence from
stroke patients shows that 20–30% of thrombi are resistant to endovascular retrieval [35]. Rt-PA also
faces some highly resistant clots, depending on the location and clot composition. Indeed, large MCA
clots are more resistant to thrombolysis, which leads to partial clot dissolution and greater tendency
for arterial reocclusion [14]. The effect of rt-PA is dependent on contact with the surface of the clot;
therefore, according to Riedel et al., short clots (length < 5 mm) are highly likely to be dissolved
completely, but recanalization could fail in more than 99% of cases if the thrombotic clot length exceeds
8 mm [36]. Furthermore, various other factors, such as the experience of the interventionalist (number
of cases performed) and the hospital setting, likely influence the success rate of recanalization.
2.2. Therapeutic Strategies for a Better “Clot-Buster”
Due to the resistance of some blood clots to rt-PA and endovascular thrombectomy, several
thrombolytics such as tenecteplase, desmoteplase and reteplase have been developed and tested in
clinical trials, but none of them were superior to rt-PA [37]. New therapeutic strategies are focusing
on increasing the rates of recanalization by combining rt-PA with other agents, such as antiplatelets
or direct thrombin inhibitors. Several antiplatelet antagonists of glycoprotein IIb/IIIa receptors
(GPIIb/IIIa) have been evaluated as potential targets in either myocardial or cerebral ischemia for
combination with thrombolysis [38]. Indeed, the administration of Tirofibran with rt-PA within 3 h
of stroke results in a better recanalization rate in the MCA, and better clinical outcome in stroke
patients [39]. The safety of the combination of Eptifibatide, another selective GPIIb/IIIa antagonist,
with rt-PA was also evaluated in the CLEAR (Combined Approach to Lysis Utilizing Eptifibatide
and rt-PA in acute ischemic stroke) trial showing that this combination of treatment can be safely
performed in stroke patients [40]. Clinical data from 65 stroke patients show that the co-administration
of rt-PA with Argatroban, a direct thrombin inhibitor, increases the fibrinolytic effect of rt-PA [41]
and enhances recanalization rates, as shown in the TARTS (rt-PA Argatroban Stroke Study) clinical
study [42]. In humans, although clinical trials evaluating the combination of antiplatelet therapy to
thrombolysis were stopped early because of an increased rate of intracerebral hemorrhage [43,44],
a recent retrospective analysis of stroke patients who received bridging thrombolysis with aspirin
during endovascular intervention showed that the combination therapy does not increase the risk of
bleeding complications [45].
Recombinant annexin A2 increases the catalytic efficiency of rt-PA in converting plasminogen to
plasmin and enhances the thrombolysis efficacy of rt-PA, with improvement of neurological outcome in
a rat model of stroke [46,47]. Combination treatment with a selective proteasome inhibitor, bortezomib,
could increase the fibrinolytic activity of rt-PA, with an associated reduction in infarct volume and
less HT compared to rt-PA alone [48,49]. Combination treatment of rt-PA with N-Acetylcysteine,
a mucolytic drug with effects on cleavage of the von Willebrand Factor (VWF), exerts increased
thrombolytic effects in a mouse model of stroke [50]. The influence of combined thrombolytics to
rt-PA deserves further experimental and clinical investigations because, as discussed before, a high
rate of patients still show no recanalization after treatment. Several antithrombotic treatments are
already available in the clinic with a favorable safety profile in stroke, myocardial infarction and acute
limb ischemia. Indeed, tirofiban has been proven to be safe in patients with ischemic stroke regarding
the risk of hemorrhagic transformation in phase II-b studies. N-acetylcysteine is also safe, and is
potentially a new, effective, thrombolytic treatment. Overall, the combined treatments with rt-PA are
promising for thrombolysis of acute stroke, and clinical trials are now needed to evaluate their efficacy.
2.3. Collaterals
The collateral circulation is a physiologic pathway of endogenous vessels that maintain residual
blood flow to brain regions distal to an arterial occlusion. Different sources of cerebral collateral flow
exist, depending on the vessel size and location. The circle of Willis constitutes the main collateral
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network in the brain and is immediately available to maintain perfusion when a large artery is
occluded. However, when occlusion occurs in an intracranial distal artery, the circle of Willis is
unable to compensate the CBF reduction, and secondary collateral flow through leptomeningeal
anastomoses is the principal alternative pathway [51]. Leptomeningeal anatomoses are cortical pial
arteries that connect the major branches of the cerebral arteries—the anterior cerebral artery (ACA),
the middle cerebral artery (MCA) and the posterior cerebral artery (ACA). The characteristic profile
of leptomeningeal collaterals is that, in these vessels, blood can flow in both directions, allowing
retrograde perfusion of adjacent territories and maintaining a viable region of brain tissue called
the “ischemic penumbra”. In the ischemic penumbra, blood flow is sufficiently reduced to arrest
physiological function, but not so completely as to cause irreversible cellular death [51]. Angiographic
data grading collateral circulation in patients with stroke revealed that final infarct size [52,53] and
functional outcome deficit vary with the presence or absence of a collateral network [54,55].
How can collateral flow impact the recanalization success?
In addition to its impact on infarct size and outcome, clinical data revealed that collaterals
also influence the success of recanalization therapy in stroke patients [56–58]. Clinical studies show
that collateral flow predicts the risk of HT after endovascular and thrombolysis therapies [59,60].
Patients with good collateral circulation show less risk of hemorrhagic complications after rt-PA
thrombolysis or mechanical revascularization, and HT occurs more frequently in patients with poor
collaterals (88.9% vs. 38.1%) [60,61]. Furthermore, the status of collateral flow is strongly related to the
recanalization rate and reperfusion after revascularization [56,59]. For example, using the MERCI clot
retriever, complete revascularization occurred in 14% of the patients with poor collaterals, in 25% of
patients with good collaterals, and in 42% of patients with excellent collaterals [56]. After intravenous
thrombolysis with rt-PA, patients with good collaterals showed higher rates of recanalization, in
comparison to those with poor collaterals (61.8% vs. 28.1%) [61].
There are several explanations for the beneficial effect of collaterals on recanalization rate in
stroke patients. First, augmented collaterals may increase the delivery of thrombolytic agents to the
clot (Figure 2). Thanks to robust collaterals, thrombolytics are able to reach the clot from different
sides, which increases the efficacy of treatment, and therefore the rate of clot lysis. Furthermore, when
the occlusive clot is dissolved, clinical data suggest that small fragments could migrate and dislodge
into distal small arterial branches downstream of the primary occlusive lesion. Collateral flow could
enhance the drug delivery to these distal branches and induce the dissolution of the fragmented
proximal microclots. Additionally, in addition to the enhanced delivery of drugs to the clot site,
collateral flow prevents impairment of vascular function and therefore improves reperfusion after
recanalization therapy. Indeed, during cerebral ischemia, the damage is not restricted to neurons.
Endothelial cells are affected as well [62–64]. Vascular damage occurring after stroke may lead to
a worse result after recanalization in patients, as it facilitates edema formation and hemorrhagic
transformation (HT). Therefore, collateral supply to the occluded vessel is crucial to reduce stroke
induced damage and increase the chance of good reperfusion after recanalization.
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Figure 2. Impact of collateral flow on clot lysis and reperfusion. (a) Schematic drawing of the collateral
network showing anastomoses between the middle cerebral artery (MCA) and anterior cerebral
artery (ACA); (b) in stroke with a poor collateral network, the collaterals fail to fill and insufficiently
compensate the flow reduction after arterial occlusion; (c) a collateral enhancement occurring in
patients showing good collateral network. The flow in the collaterals changes direction and allows the
thrombolytic to reach the drug from different sides.
2.4. Strategies to Enhance Collateral Circulation
Despite the important contribution of collateral circulation maintaining the penumbra and
improving blood flow in ischemic brain tissue, the collateral network has been neglected in previous
stroke studies. Recent studies have suggested that collateral flow could be enhanced by adjusting
head position and intravenous fluid support, while others have tested pharmacological-induced
hypertension, vasodilation and hemodilution [65,66].
The beneficial effects of induced hypertension have been confirmed in animal models of
stroke [67]. Intravenous infusion of phenylephrine increased blood pressure, and was associated
with reduced infarct volume, as well as improved reperfusion in rat and rabbit animal models
of stroke [68,69]. However, although mild hypertension induced during acute stroke appears to
be protective, chronic hypertension paradoxically worsens stroke outcome [70]. The safety and
efficacy of induced hypertension using phenylephrine in patients with ischemic stroke is under
investigation in the clinical trial SETIN-HYPERTENSION (The Safety and Efficacy of Therapeutic
Induced HYPERTENSION in acute ischemic stroke) [71]. As a hemodiluting agent, albumin has been
shown to increase collateral formation and enhance reperfusion after distal MCA occlusion in mice [72].
However, the clinical trial ALIAS (Albumin in Acute Ischemic) showed that treatment with intravenous
albumin in stroke patients was not associated with improved outcome at 90 days, and was associated
with increased rates of HT and pulmonary edema [73]. Collateral flow improvement by chemokines
and growth factors, including vascular endothelial growth factor (VEGF) and statins, has also been
evaluated in ischemic stroke. Harrigan et al. reported that VEGF infusion in middle cerebral artery
occlusion (MCAO) rats increased the vascular density in a dose-dependent manner and minimized
the associated brain edema after ischemic stroke [74]. Ovbiagele et al. have shown that statins may
enhance the collateral supply in stroke and patients using statins as pretreatment have significantly
higher collateral scores than the non-statin users [75]. Statins are safe in stroke, as has been shown in
clinical trials, and the combination of rt-PA to simvastatin in patients is associated with low rates of
bleeding complication (STAR Stroke Treatment With Acute Reperfusion and Simvastatin trial) [76].
However, the STARS trial was underpowered for detecting differences in simvastatin efficacy because
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of the low recruitment rates. To the best of our knowledge, there is still no clinical data supporting the
use of medical therapies targeted at the enhancement of the collateral network.
3. No Reperfusion Despite Recanalization Successes (Futile Recanalization)
As mentioned above, successful recanalization does not consistently lead to better outcomes in
stroke patients, as more than 50% of patients with successful rt-PA thrombolysis or thrombectomy
have an unfavorable outcome [5,21]. This “futile recanalization”, which occurs after removal of the
causative clot, has been attributed to “arterial reocclusion” and to the “no-reflow phenomenon” [24,25].
3.1. Arterial Reocclusion
Arterial reocclusion is defined as a subsequent occlusion of a target vessel after initial
recanalization. Clinically, the occurrence of the vascular reooclusion is characterized by a brief
initial clinical improvement (due to successful recanalization) followed by a deterioration (due to
reocclusion) in the absence of intracranial hemorrhage. In the National Institute of Neurological
Disorders and Stroke (NINDS) trial, 13% of patients treated with rt-PA experienced an early clinical
deterioration after an initial improvement, representing arterial reocclusion [77]. In other clinical
studies, arterial reocclusion has been documented in about 20 to 34% of rt-PA-treated patients after
successful thrombolysis [28,29]. This high proportion of arterial reocclusion (higher than the rate
of HT) observed in most academic stroke centers emphasizes the need to better understand this
vascular complication. Early reocclusion following successful recanalization is associated with a
significantly poorer outcome at 3 months and a higher in-hospital mortality compared to patients
without reocclusion [28]. However, patients with reocclusion still have better long-term outcomes and
less mortality than patients without any early recanalization [28]. These data suggest that even a brief
recanalization before arterial reocclusion induces a beneficial effect in stroke patients.
Subacute reocclusion occurs within the first 2 h after recanalization in cerebral vessels following
the administration of thrombolytic agents or endovascular therapy [14,28,78]. Arterial reocclusions
are more frequent when the recanalization is incomplete. Indeed, clinical data show that partial clot
dissolution after thrombolysis is associated to a greater tendency for reocclusion [14]. Several factors
are involved in the mechanisms of arterial reocclusion such as migration of dissolved clots that occlude
distal arterial branches or reformation of new thrombus. The reformation of new thrombus at the site of
occlusion have been studied in the coronary circulation as well as the cerebral circulation [79]. Although
thrombolytic therapy is able to dissolve occlusive thrombi, it creates a procoagulant environment
by generating plasmin [80]. The plasmin activates platelets and generates thrombin, increasing the
likelihood of vessel reocclusion [80]. The use of endovascular clot retrieval may also activate the
clotting cascade because of a disruption of atherosclerotic plaques or endothelial erosion that triggers
platelet activation, adherence and aggregation, and also the exposure of tissue factor [79,80].
3.2. Therapeutic Targets against Arterial Reocclusion
Currently, there is limited information about detailed mechanistic aspects of the reocclusion
process. As arterial reocclusion could be a major contributor to futile recanalization, more preclinical
investigations are necessary to assess possible molecular pathways and therapeutic targets related
to reocclusion scenarios. These strategies should focus on the activation of the coagulation cascade
and the infiltration of procoagulation factors such as TAFI (thrombin-activatable fibrinolysis inhibitor)
and PAI-1 (plasminogen activator inhibitor-1) and on the vascular dysfunction and constriction after
reperfusion. All of these factors may be able to impact reocclusion rate after reperfusion, but more
studies are necessary to arrive at a concrete recommendation.
3.3. No-Reflow
No-reflow describes a failure of microcirculatory reperfusion despite clot removal. Ames and
coworkers were the first to describe the “no-reflow” phenomenon in 1968. They described an
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incomplete cerebral blood-flow restoration after mechanical recanalization in a rabbit model of
cerebral ischemia [81]. Angiograms from stroke patients confirmed the existence of no-reflow in
the clinic; in some cases, although clots were completely dissolved and the vascular patency restored,
the reperfusion in stroke patients was non-existent [82,83]. Furthermore, data from stroke patients
confirm that tissue reperfusion is a more accurate predictor of outcome after thrombolysis than
recanalization [23]. When the post-stroke microvascular no-reflow occurs, it attenuates the beneficial
impact of reperfusion, resulting in poor clinical outcomes [84,85]. Although clinical data show
microvascular perfusion failure after recanalization, little is known about the mechanisms of no-reflow,
because it is difficult to assess, both in clinical imaging and in experimental models [86]. Experimental
data from a mouse model of stroke demonstrated that after successful intravenous thrombolysis, about
half of the capillaries remain constricted [26]. Narrowing of the microvascular lumen was attributed to
a compression caused by swollen astrocyte end feet and endothelial cells [87,88]. Several years later,
Yemisci and colleagues showed that pericytes are also involved in the capillary constriction, leading
to a reduced lumen and an incomplete microcirculatory reperfusion [26]. Constricted microvessels
after stroke show narrowed lumina, entrapped erythrocytes, leukocytes and fibrin-platelets deposits.
After recanalization, the fibrin and platelets deposit in the capillaries are associated to the areas with
remaining hypoperfusion in rat brain after cerebral ischemia [89].
In addition to the microvascular constriction, a primary clot can break into fragments that
migrate and occlude smaller arterial branches downstream of the primary occlusive lesion [90].
Microclots have been found in brain microvessels of stroke patients who died within a month after
the stroke onset [91]. Another important factor contributing to the no-reflow phenomenon during
reperfusion is the impairment of vascular patency after stroke. Cerebral ischemia is known to impair
the dilation ability of arterioles in response to endothelium-dependent vasodilators, such as nitric
oxide (NO) and acetylcholine (Ach) [62,92]. Reduced endothelial vasoreactivity was reported after
cerebral ischemia/reperfusion, and could contribute to the impairment of blood flow restoration [62].
Permanent and transitory cerebral ischemia alter the ability of relaxation in the microvascular bed and
the perfusion in the downstream capillary. This altered vascular reactivity is due to a reduced release
of nitric oxide (NO) after stroke and reperfusion [93–96]. The reduced release of NO could lead to
pericyte contraction and erythrocyte entrapment [26].
3.4. Therapeutic Strategies for Treatment of No-Reflow
At present, there are no specific therapies targeting no-reflow after stroke. In myocardial infarction,
no-reflow is a field of intense research, and the treatment of no-reflow is based on vasodilators like
adenosine and verapamil, GPIIb/IIIa receptor blockers, intra-coronary Ca2+ blockers, as well as
clearance of microvascular plugging [97]. In cerebral ischemia, very few therapies have been tested,
but it has been suggested that reducing microvascular clogging by inhibiting fibrin or platelets and
leukocyte adherence or vascular inflammation restores microcirculation, reduces no-reflow, and
improves stroke outcome in animal models [98–101]. However, these strategies have never been
evaluated in clinic, due to the difficulties in assessing the microvascular reperfusion in stroke patients.
Cilostazol, a phosphodiesterase inhibitor acting as an antiplatelet agent, reduced the no-reflow and
HT induced by rt-PA, via maintenance of microvascular integrity in a MCAO mouse model [102].
Administration of a direct thrombin inhibitor, argatroban, enhances the recanalization rates induced
by rt-PA by preventing the no-reflow [41]. Administration of Pioglitazone, an activator of peroxisome
proliferator-activated receptor-gamma (PPARγ), reduces the no-reflow phenomenon in microvessels
after MCAO in rats [103]. Furthermore, adhesion molecule-blocking antibodies that inhibit leukocyte
adhesion, such as P-selectin, E-selectin, and ICAM-1, also improve the rt-PA induced reperfusion
in post-ischemic cerebral mouse brains by preventing no-reflow [98,100,101]. Due to the multiple
functions of pericytes in the microcirculatory system, development of drugs targeting pericytes is
a promising new strategy for the prevention and treatment of the no-reflow phenomenon. Pericyte
dilatation could be mediated mainly by NO [104]. Moreover, some signals of increased energy
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utilization, including lactates, adenosine and low pH, could also be investigated for their relaxing
properties on pericytes [105].
4. Reperfusion with Vascular Complications
In addition to recanalization and reperfusion failure, tissue hemorrhage may occur after
recanalization therapy in stroke patients. This is one of the most feared complications of stroke
thrombolysis and thrombectomy, because it is potentially life threatening.
4.1. Hemorrhagic Transformation
Hemorrhagic transformation (HT) refers to bleeding into an ischemic area in a primarily ischemic
stroke. Symptomatic HT occurs in a significant proportion of patients, and is associated with
neurological deterioration and increased mortality. The HT rate after cerebral ischemia varies between
10% and 40%, depending on individual factors such as age, blood glucose level, and the time window
allowed for the initiation of the therapy [106,107]. Thrombolysis with rt-PA increases the rate of HT by
6–10 fold [6,108]. However, the increase of HT with rt-PA is not always clinically relevant, and it is
still a matter of debate as to how rt-PA could enhance the extent of HT, and at the same time improve
patients’ functional outcomes [109,110]. Indeed, clinical data from both European Cooperative Acute
Stroke Studies (ECASS) 1 and 2 indicate that, although rt-PA increases the risk of HT, it reduces the
overall risk for disability and death by 6% and 8%, respectively [111,112]. To explain this contradiction,
Von Kummer et al., suggested that the risk of HT after thromobolysis has been overestimated, and that
some imaging-defined HT lesions represent reperfusion following successful and early recanalization
after administration of rt-PA [110,113,114].
Reperfusion of a severely ischemic tissue may lead to deleterious consequences, known as the
reperfusion injury, which leads to the disruption of the blood brain barrier (BBB). Reperfusion increases
the production of oxygen radicals, which involves formation of hydrogen peroxide, hydroxy radicals,
and superoxide [115–117]. These radicals result in increased BBB permeability, disruption of endothelial
cell membranes, increased platelet aggregability and alterations in vascular response to CO2 [116].
Accordingly, it is now well established that reperfusion is a key factor in HT [118]. By using magnetic
resonance imaging in stroke patients, it was shown that rt-PA is associated with BBB breakdown,
which is correlated to HT [119,120].
Furthermore, beyond its role in thrombolysis and reperfusion injury, rt-PA may promote
HT through other mechanisms, such as increasing metalloproteinase activity and the low-density
lipoprotein receptor-related protein (LRP) receptor signaling [118,119,121]. rt-PA increases the matrix
metalloproteinases MMP-2 [122], MMP-3 [123] MMP-9 levels in the brain [124]. Metalloproteinases
(MMPs) are responsible for the degradation of the extracellular matrix and vascular basement
membrane that leads to BBB breakdown. The activity of the MMPs increases after rt-PA administration,
especially MMP-9, which has been shown to be elevated in venous blood from stroke patients that
received rt-PA treatment [125,126]. Furthermore, rt-PA can promote the degranulation of neutrophils
into the blood. Since neutrophils are the main source of MMP-9, the rt-PA induced degranulation
increase the MMP level and the thrombolysis-related brain bleedings [127]. rt-PA is also capable of
interacting with the LRP on endothelial cells and enhance the release of MMP-3 and MMP-9 as well as
the detachment of astrocytic end-feet leading to a dysregulation of the BBB [128,129].
4.2. Strategies against Hemorrhagic Transformation
Several therapies have been evaluated for the prevention of HT induced by reperfusion therapies.
The molecular targets that have been evaluated for HT prevention include inhibiting MMPs, reducing
oxygen radicals, and modulating targets that affect BBB permeability.
Free-radical scavengers aiming to reduce stress oxidants, such as edaravone, uric acid
and NXY-059 protect the BBB and reduce HT induced by rt-PA in animal models of cerebral
ischemia [130–133]. However, targeting the stress oxydant failed to show beneficial effects in
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clinical trials, and treated stroke patients did not show any signs of clinical improvement [131,133].
Inhibition of MMP by pharmacological drugs such as Batimastat (BB-94) and minocycline reduces BBB
permeability and the rate of rt-PA related in rats and rabbit models of stroke [134,135]. Furthermore,
in experimental models of stroke, several therapies also showed reduction of the rt-PA-related hat,
such as cilostazol [102], fasudil (rho kinase inhibitor) [136], fingolimod (sphingosine 1-phosphate
receptor agonist) [137], polyADP ribose polymerase (PARP) inhibitors [138,139], FK506 (tacrolimus,
immusupressive drug) [140], and VEGF inhibition [141,142]. Although preclinical studies have
demonstrated the potential effect of several drugs to reduce the rt-PA induced HT, few are under
investigation in clinic. Edaravone stroke trial PROTECT 4.5 has shown that the frequency of
intracerebral HT is lower with combined rt-PA to edaravone than with rt-PA alone [143]. Albumin,
minocycline and simvastatin are also under investigation in clinical trials [144].
5. Conclusions and Future Direction
After cerebral ischemia, blood flow disruption limits the delivery of glucose and oxygen
to neurons, causing a cascade of energy failure events, and a complex series of biochemical
events including neuroinflammation, excitotoxicity, oxidative and nitrative stress, Ca2+ influx and
proapoptotic cascade activation [145,146]. Decades of research has focused on the neural consequences
after stroke by searching for new neuroprotective strategies, but translation into clinical therapies has
been difficult [147]. Researchers have outlined a variety of reasons for this clinical failure; mainly
lack of efficacy, intolerable side effects of the treatments, or issues regarding quality and conduct
of experimental research studies [148,149]. However, the vascular injury of stroke per se has been
neglected, thus far. It is possible that neuroprotective therapies have failed in humans because the
damaged vascular network is unable to deliver the necessary nutrients and treatment to the tissue at
risk, thus also hampering neuroprotection.
There are theoretical reasons and evidence from animal experimentation, as well as clinical trials,
suggesting that CBF restoration is a key determinant of better outcomes in stroke patients. Accordingly,
when reperfusion therapy is executed, not only should the clot be removed, but the vessels should
also be protected to restore physiological reperfusion. However, different states of vascular patency
and function after recanalization in stroke contribute to treatment success: some could hamper the
benefit of recanalization (no-reflow, reocclusion and HT) and others could enhance it (collaterals).
Some vascular phenomena such as HT have been widely investigated in stroke, while others, such as
the reocclusion, collaterals and no-reflow, remain relatively understudied. Therefore, there is an urgent
need to gain additional mechanistic insight into the molecular events that are triggered by reperfusion,
and which could be exploited therapeutically. Understanding the role of vascular pathology after
stroke should be a prioritized research goal, in order to increase the chance of successful translation of
treatments into the clinic and, most of all, to improve patients’ recovery.
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